Skip to content

Research at St Andrews

In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract

Research output: Contribution to journalArticle

Author(s)

Thanyaluck Siriyong, Julalak Chorachoo Ontong, Sukanlaya Leejae, Sakol Suwalak, Peter John Coote, Supayang Piyawan Voravuthikunchai

School/Research organisations

Abstract

Background

Rhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models.

Material and Methods

Safety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured.

Results

Treatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days.

Conclusions

As the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.

Close

Details

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalToxicology Reports
Volume7
DOIs
Publication statusPublished - 31 Jul 2020

    Research areas

  • Toxicity, Rhodomyrtone, Invertebrate, Vertebrate

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition

    Siriyong, T., Murray, R. M., Bidgood, L. E., Young, S. A., Wright, F., Parcell, B. J., Voravuthikunchai, S. P. & Coote, P. J., 24 Jun 2019, In : Scientific Reports. 9, 13 p., 9098.

    Research output: Contribution to journalArticle

ID: 269483823

Top